Telix Pharmaceuticals (TLX) Current Leases (2023 - 2026)

Telix Pharmaceuticals (TLX) has reported Current Leases for 3 consecutive years, with $5.5 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Current Leases rose 239.89% year-over-year to $5.5 million; the TTM figure through Dec 2025 stood at $5.5 million (up 239.89% YoY), while the FY2025 annual figure was $5.5 million, up 258.86% from the prior year.
• Current Leases rose to $5.5 million in Q4 2025 per TLX's latest filing, from $1.6 million in the prior quarter.
• Across five years, Current Leases topped out at $5.5 million in Q4 2025 and bottomed at $387339.3 in Q4 2023.
• Historically, Current Leases has averaged $2.5 million across 3 years, with a median of $1.6 million in 2024.
• Annual changes were most pronounced in 2024 — Current Leases jumped 321.41% — and 2025, when it jumped 239.89%.
• Telix Pharmaceuticals' Current Leases stood at $387339.3 in 2023, then surged by 321.41% to $1.6 million in 2024, then surged by 239.89% to $5.5 million in 2025.
• Business Quant data shows TLX's Current Leases at $5.5 million in Q4 2025, $1.6 million in Q4 2024, and $387339.3 in Q4 2023.